Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan clinical oncology group study, JCOG0112

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 586-589

  Chou, Takaaki ^a   Tobinai, Kensei ^b   Uike, Naokuni ^c   Asakawa, Takashi ^d   Saito, Isamu ^d   Fukuda, Haruhiko ^d   Mizoroki, Fumi ^e   Ando, Kiyoshi ^f   Iida, Shinsuke ^g   Ueda, Ryuzo ^g   Tsukasaki, Kunihiro ^h   Hotta, Tomomitsu ⁱ  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NAGOYA CITY UNIVERSITY   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Chemo Phase III; IFN PSL; MP VAD; Myeloma

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL;

AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSTIPATION; DEXAMETHASONE; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; HUMANS; INTERFERONS; JAPAN; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; PREDNISONE; REMISSION INDUCTION; VINCRISTINE;

EID: 79953759456     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq245     Document Type: Article

References (17)

1. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
2. Takenaka T, Itoh K, Suzuki T, Utsunomiya A, Matsuda S, Chou T, et al. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/ MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301. Int J Hematol 2004;79:165-73.
3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
5. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2:882-5.
6. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11:1427-36.
7. The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020-34.
8. McIntyre OR, Pajak TF, Kyle RA, Cornwell GG, III, Leone L. Response rate and survival in myeloma patients receiving prednisolone alone. Med Pediatr Oncol 1985;13:239-43.
9. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-90.
10. Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998;16:890-6.
11. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163-8.
12. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
14. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
15. NCI-CTC version 2.0, April 30, 1999.
16. Sunami K, Shinagawa K, Sawamura M, Sakai A, Saburi Y, Imamura Y, et al. Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma. Int J Hematol 2009;90:635-42.
17. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.